Boston Scientific price target lowered to $95 from $115 at Argus

Argus lowered the firm’s price target on Boston Scientific (BSX) to $95 from $115 but keeps a Buy rating on the shares after its Q1 results and guidance cut. The stock has underperformed the broader market recently, but the company remains well positioned in high growth areas such as cardiovascular, electrophysiology, and neuromodulation, and the management has set more-achievable objectives by cutting its outlook, the analyst tells investors in a research note. Argus adds that the price weakness in Boston Scientific creates a buying opportunity.